NEC Oncoimmunity bags $4.8M to develop vaccines for SARS-CoV-2 variants, other betacoronaviruses April 11, 2022 By Gina Lee NEC Corp. subsidiary NEC Oncoimmunity AS recently received $4.8 million from the Coalition for Epidemic Preparedness Innovations to fund the development of vaccines for SARS-CoV-2 variants and other betacoronaviruses.Read More
ADAM17 inhibition alleviates COVID-19-associated cytokine storm in lung epithelial cells April 11, 2022
Human neutralizing antibody against PUUV spike broadly protects rodent models against hantaviruses April 11, 2022
Emergex collaborates with nonprofit organization to advance yellow fever booster vaccine candidate April 7, 2022
Peptidomimetic TMPRSS2 inhibitor shows prophylactic and therapeutic activity against SARS-CoV-2 VOCs April 7, 2022
RSS
